drugset / Trial / NCT00004085
Radioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer
Phase 1/2
Completed
15 enrolled
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by radioimmunotherapy used to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody therapy plus peripheral stem cell transplantation in treating patients who have stage IV breast cancer.
Timeline
- Start
- 1998-05
- Primary completion
- 2002-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YTTRIUM Y 90 LABETUZUMAB | Monoclonal antibody | — | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |